Analysts Offer Insights on Healthcare Companies: Atara Biotherapeutics (NASDAQ: ATRA), United Therapeutics (NASDAQ: UTHR) and ANI Pharmaceuticals Inc (NASDAQ: ANIP)

By Ryan Adsit

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Atara Biotherapeutics (NASDAQ: ATRA), United Therapeutics (NASDAQ: UTHR) and ANI Pharmaceuticals Inc (NASDAQ: ANIP).

Atara Biotherapeutics (NASDAQ: ATRA)

Canaccord Genuity analyst John Newman assigned a Buy rating to Atara Biotherapeutics (NASDAQ: ATRA) today and set a price target of $47. The company’s shares opened today at $16.25.

According to TipRanks.com, Newman is a 4-star analyst with an average return of 4.2% and a 39.2% success rate. Newman covers the Healthcare sector, focusing on stocks such as Advanced Accelerator Applications, Hutchison China MediTech Ltd, and Synergy Pharmaceuticals Inc.

Atara Biotherapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $33.

United Therapeutics (NASDAQ: UTHR)

In a report issued on December 27, Chris Shibutani from Cowen & Co. assigned a Hold rating to United Therapeutics (NASDAQ: UTHR), with a price target of $129. The company’s shares opened today at $150.09.

According to TipRanks.com, Shibutani is a 4-star analyst with an average return of 18.0% and a 53.8% success rate. Shibutani covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Lexicon Pharmaceuticals, and Five Prime Therapeutics.

United Therapeutics has an analyst consensus of Moderate Buy, with a price target consensus of $157.75.

ANI Pharmaceuticals Inc (NASDAQ: ANIP)

In a report released today, Dewey Steadman from Canaccord Genuity maintained a Buy rating on ANI Pharmaceuticals Inc (NASDAQ: ANIP), with a price target of $77. The company’s shares opened today at $63.53.

Steadman observed:

“We view ANI’s recent purchase of four tail branded assets from AstraZeneca positively and we think the transaction is consistent with prior value-creating moves at the company. From the transaction, ANI will gain four modest but highly profitable branded products with the opportunity to expand margins further through in-sourcing manufacturing for the basket. Additionally, ANI enhanced its BD flexibility through a new credit facility that gives the company ample capacity to pursue additional transactions. With a solid core business and significant optionality associated with the Cortrophin development asset, we view ANI as one of the best-positioned names in our emerging generics space.”

According to TipRanks.com, Steadman is a 1-star analyst with an average return of -1.2% and a 40.3% success rate. Steadman covers the Healthcare sector, focusing on stocks such as Infotek Pharmaceuticals, Pacira Pharmaceuticals, and Cardiome Pharma Corp.

ANI Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $70.50.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.